Health

CellMax-LBx Liquid Biopsy California-based #CellMax Life, the precision cancer testing company, said its CellMax-LBx Liquid Biopsy is available in India. CellMax-LBx is a cancer blood test which analyzes circulating tumor #DNA (ctDNA). The assay provides oncologists with a valuable tool...

Raloxifene launched Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista® (raloxifene hydrochloride) tablets in the United States. It has been approved by the...

Renewables efforts noted India could have been expected to increase its coal-fired power use for decades, but it has now intensified focus on renewables, notes Climate Action Tracker (CAT). There appears to be a transition underway with an extremely rapid...

Acne dose VB 1953 Delhi-based Vyome Biosciences has administered the first in-human dose of its lead candidate VB 1953 in its Phase 1 clinical trial being conducted in the United States to treat patients with moderate to severe facial acne....

Aripiprazole tablets Dr. Reddy’s Laboratories Ltd has launched Aripiprazole tablets, USP, a therapeutic equivalent generic version of Abilify® (aripiprazole) tablets in the United States. Approved by the U.S. Food & Drug Administration (USFDA), Dr. Reddy’s Aripiprazole tablets 2 mg, 5...

Dr Reddy's tablets in US Dr. Reddy’s Laboratories Ltd has launched Lamotrigine Orally Disintegrating Tablets in 25 mg, 50 mg, 100 mg, and 200 mg, a therapeutic equivalent generic version of Lamictal® ODT (lamotrigine) Orally Disintegrating Tablets in the United...

Amgen's three medicines Dr. Reddy’s Laboratories Ltd has expanded its strategic collaboration with Amgen to market and distribute the latter’s three medicines in India in the therapy areas of oncology and osteoporosis. Dr. Reddy’s will commercialise XGEVA® (denosumab), Vectibix® (panitumumab)...

Dr Reddy's acquisition Dr. Reddy’s Laboratories Ltd has completed the previously announced acquisition of eight Abbreviated New Drug Applications (ANDAs) in the U.S. from Teva Pharmaceutical Industries Ltd and an affiliate of Allergan plc. The acquired portfolio consists of products that are being...

New Act for e-pharmacy The Government is working towards drafting a new Drugs & Cosmetics Act, 2016 to meet the current regulatory requirements related to safety, efficacy and quality of drugs, said Dr. S. Eswara Reddy, Joint Drugs Controller, Central Drugs...

Excelra-Astellas collaborates   Hyderabad’s Excelra, a leading Knowledge Solutions Company, has entered into a strategic Drug Repurposing collaboration with Tokyo-based pharmaceutical company, Astellas Pharma Inc. The collaboration is focused on identifying novel therapeutic indications for a number of undisclosed Astellas’...